Axsome Therapeutics (AXSM) Gross Margin (2022 - 2026)
Axsome Therapeutics (AXSM) reported Gross Margin of 92.3% for Q1 2026, up 36.0% on a YoY basis from 67.87% in Q1 2025, and down 1.51% sequentially from 93.71% in Q4 2025.
Axsome Therapeutics (AXSM) Gross Margin (2022 - 2026) Analysis & Trends
Axsome Therapeutics (AXSM) has 5 years of Gross Margin data on file, last reported at 92.3% in Q1 2026.
- For the quarter ending Q1 2026, Gross Margin rose 36.0% year-over-year to 92.3%; the trailing twelve-month figure through Mar 2026 stood at 92.6% (up 432.0% YoY), and the FY2025 full-year result was 92.56%, up 120.0% from the prior year.
- Gross Margin eased to 92.3% in Q1 2026, from 93.71% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 93.71% in Q4 2025 to a low of 2002.8% in Q4 2024.
- A 5-year average of 39.87% and a median of 90.9% in 2025 frame the typical range for Gross Margin.
- Across the five-year window, Gross Margin sank 209249 bps in 2024 and soared 209651 bps in 2025, its largest moves.
- Tracing AXSM's Gross Margin over 5 years: stood at 90.6% in 2022, then slipped by 1 bps to 89.69% in 2023, then plunged by 2333 bps to 2002.8% in 2024, then jumped by 105 bps to 93.71% in 2025, then declined by 2 bps to 92.3% in 2026.
- Business Quant data shows AXSM's Gross Margin at 92.3% in Q1 2026, 93.71% in Q4 2025, and 93.03% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,583.17 Bn | 67,582.89 Bn | - | - |
| 2 | Nanobiotix | 1,941.00 Bn | 1,940.94 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.62 Bn | 468.83 Bn | 1.35 Bn | 88.95% |
| 5 | Vertex Pharmaceuticals | 123.20 Bn | 115.95 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.30 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.96 Bn | 62.96 Bn | - | - |
| 8 | Argenx Se | 56.57 Bn | 51.38 Bn | 1.41 Bn | 90.68% |
| 9 | Alnylam Pharmaceuticals | 37.59 Bn | 34.58 Bn | 959.66 Mn | 82.22% |
| 10 | Axsome Therapeutics | 12.36 Bn | 12.06 Bn | 176.48 Mn | 92.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92.30% |
| Dec 31, 2025 | 93.71% |
| Sep 30, 2025 | 93.03% |
| Jun 30, 2025 | 91.04% |
| Mar 31, 2025 | 91.94% |
| Dec 31, 2024 | -2,002.80% |
| Sep 30, 2024 | 91.95% |
| Jun 30, 2024 | 90.76% |
| Mar 31, 2024 | 91.60% |
| Dec 31, 2023 | 89.69% |
| Sep 30, 2023 | 88.70% |
| Jun 30, 2023 | 90.15% |
| Mar 31, 2023 | 92.01% |
| Dec 31, 2022 | 90.60% |
| Sep 30, 2022 | 88.58% |
| Jun 30, 2022 | 88.85% |